NasdaqGM:DRAD

Stock Analysis Report

Executive Summary

Digirad Corporation provides healthcare solutions in the United States and internationally.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Share Price & News

How has Digirad's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

6.0%

DRAD

5.8%

US Healthcare

1.8%

US Market


1 Year Return

-66.3%

DRAD

-6.5%

US Healthcare

7.3%

US Market

Return vs Industry: DRAD underperformed the US Healthcare industry which returned -6.5% over the past year.

Return vs Market: DRAD underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

DRADIndustryMarket
7 Day6.0%5.8%1.8%
30 Day-6.7%2.5%-0.7%
90 Day-15.0%-1.8%0.06%
1 Year-66.3%-66.3%-5.0%-6.5%9.7%7.3%
3 Year-89.5%-91.0%33.9%28.6%46.3%36.9%
5 Year-86.3%-89.2%65.6%55.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is Digirad's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Digirad undervalued compared to its fair value and its price relative to the market?

0.4x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate DRAD's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate DRAD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DRAD is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.

PE vs Market: DRAD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate DRAD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DRAD is good value based on its PB Ratio (0.4x) compared to the US Healthcare industry average (2.5x).


Next Steps

Future Growth

How is Digirad forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Digirad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Digirad performed over the past 5 years?

-47.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: DRAD is unprofitable, and losses have increased over the past 5 years at a rate of -47.7% per year.

Accelerating Growth: Unable to compare DRAD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DRAD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (5.3%).


Return on Equity

High ROE: DRAD has a negative Return on Equity (-22.54%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: DRAD is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: DRAD is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Digirad's financial position?


Financial Position Analysis

Short Term Liabilities: DRAD's short term assets ($21.1M) exceeds its short term liabilities ($14.8M)

Long Term Liabilities: DRAD's short term assets (21.1M) exceeds its long term liabilities (19.8M)


Debt to Equity History and Analysis

Debt Level: DRAD's debt to equity ratio (66%) is considered high

Reducing Debt: Insufficient data to determine if DRAD's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: DRAD has a high level of physical assets or inventory.

Debt Coverage by Assets: DRAD's debt is covered by short term assets (assets are 1.375790x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DRAD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: DRAD has less than a year of cash runway if free cash flow continues to reduce at historical rates of -42.4% each year


Next Steps

Dividend

What is Digirad's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

company0%marketbottom25%1.5%markettop25%3.7%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate DRAD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DRAD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if DRAD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DRAD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: DRAD is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DRAD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Digirad's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Matt Molchan (52yo)

6.3yrs

Tenure

US$637,997

Compensation

Mr. Matthew Gabel Molchan, also known as Matt, has been the Chief Executive Officer and Director of Digirad Corporation since July 01, 2013 and has been its President from February 2013. Mr. Molchan served ...


CEO Compensation Analysis

Compensation vs. Market: Matt's total compensation ($USD638.00K) is about average for companies of similar size in the US market ($USD491.38K).

Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.8yrs

Average Tenure

52yo

Average Age

Experienced Management: DRAD's management team is considered experienced (3.8 years average tenure).


Board Age and Tenure

6.5yrs

Average Tenure

50yo

Average Age

Experienced Board: DRAD's board of directors are considered experienced (6.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$19,20020 May 19
David Noble
EntityIndividual
Role
Chief Financial Officer
CFO & COO
Shares3,000
Max PriceUS$6.40
BuyUS$5,55017 May 19
David Noble
EntityIndividual
Role
Chief Financial Officer
CFO & COO
Shares853.8
Max PriceUS$6.50
BuyUS$28,38017 May 19
Mitchell Quain
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares3,800
Max PriceUS$7.50
BuyUS$27,20017 May 19
Jeffrey Eberwein
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares4,000
Max PriceUS$7.30
BuyUS$46,92015 May 19
Mitchell Quain
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares6,900
Max PriceUS$6.80
BuyUS$6,68015 May 19
Jeffrey Eberwein
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares1,000
Max PriceUS$7.10
BuyUS$178,60009 May 19
Jeffrey Eberwein
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares26,000
Max PriceUS$7.00
BuyUS$12,99419 Mar 19
Michael Cunnion
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,624.2
Max PriceUS$8.00
BuyUS$74,33019 Mar 19
Mitchell Quain
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares9,780.3
Max PriceUS$7.60
BuyUS$17,00019 Mar 19
Matthew Molchan
EntityIndividual
Role
Chief Executive Officer
President
Shares2,000
Max PriceUS$8.50
BuyUS$4,92019 Mar 19
John Climaco
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares600
Max PriceUS$8.20
BuyUS$32,80018 Mar 19
David Noble
EntityIndividual
Role
Chief Financial Officer
CFO & COO
Shares4,000
Max PriceUS$8.20
BuyUS$11,10015 Mar 19
Jeffrey Eberwein
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares1,500
Max PriceUS$7.40
BuyUS$16,66216 Nov 18
David Noble
EntityIndividual
Role
Chief Financial Officer
CFO & COO
Shares1,584.2
Max PriceUS$10.60
BuyUS$28,75013 Nov 18
Jeffrey Eberwein
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares2,500
Max PriceUS$11.50

Ownership Breakdown


Management Team

  • Matt Molchan (52yo)

    President

    • Tenure: 6.3yrs
    • Compensation: US$638.00k
  • Martin Shirley (57yo)

    President of Digirad Imaging Solutions

    • Tenure: 3.8yrs
    • Compensation: US$321.37k
  • Bob Halbert

    Senior Director of Human Resource

    • Tenure: 0yrs
  • David Noble (49yo)

    CFO & COO

    • Tenure: 0.8yrs
  • Hannah Bible

    Vice President of Legal

    • Tenure: 0yrs

Board Members

  • Mitch Quain (67yo)

    Independent Director

    • Tenure: 0.8yrs
  • John Sayward (67yo)

    Independent Director

    • Tenure: 11.6yrs
    • Compensation: US$78.50k
  • Matt Molchan (52yo)

    President

    • Tenure: 6.3yrs
    • Compensation: US$638.00k
  • Mike Cunnion (48yo)

    Independent Director

    • Tenure: 5.8yrs
    • Compensation: US$72.13k
  • John Climaco (50yo)

    Independent Director

    • Tenure: 6.8yrs
    • Compensation: US$68.13k
  • Mickey King

    Executive Chairman of Digirad Imaging Solutions

    • Tenure: 7.8yrs
  • Jeff Eberwein (49yo)

    Independent Chairman

    • Tenure: 6.7yrs
    • Compensation: US$75.00k
  • Dimitrios Angelis (49yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$72.13k

Company Information

Digirad Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Digirad Corporation
  • Ticker: DRAD
  • Exchange: NasdaqGM
  • Founded: 1985
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$9.222m
  • Shares outstanding: 2.04m
  • Website: https://www.digirad.com

Number of Employees


Location

  • Digirad Corporation
  • 1048 Industrial Court
  • Suite E
  • Suwanee
  • Georgia
  • 30024
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DRADNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 2004
FDV1DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2004
DRAD.PNasdaqGM (Nasdaq Global Market)CUM PFD SR AUSUSDSep 2019

Biography

Digirad Corporation provides healthcare solutions in the United States and internationally. It operates through three segments: Diagnostic Services, Mobile Healthcare, and Diagnostic Imaging. The Diagnosti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 23:52
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.